Articles with "lorlatinib" as a keyword



Photo by nci from unsplash

Novel ARHGAP23‐FER fusion in a metastatic spindle cell–predominant neoplasm with a myofibroblastic phenotype and a sustained metabolic response to lorlatinib

Sign Up to like & get
recommendations!
Published in 2021 at "Cancer"

DOI: 10.1002/cncr.33854

Abstract: Cancer November 15, 2021 Soft tissue sarcomas (STSs) are a varied group of malignancies characterized by an evergrowing list of potential underlying genetic alterations. Although many STSs have a limited sensitivity to cytotoxic chemotherapy, identification… read more here.

Keywords: fusion metastatic; arhgap23 fer; fer fusion; novel arhgap23 ... See more keywords
Photo by erol from unsplash

The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants

Sign Up to like & get
recommendations!
Published in 2019 at "Investigational New Drugs"

DOI: 10.1007/s10637-019-00872-7

Abstract: Background The third-generation tyrosine kinase inhibitor lorlatinib is approved for the treatment of ALK-positive metastatic NSCLC. CYP3A plays a major role in lorlatinib metabolism; therefore, a drug-drug interaction study was warranted to evaluate the impact… read more here.

Keywords: healthy participants; period; study; phase open ... See more keywords
Photo by kellysikkema from unsplash

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners

Sign Up to like & get
recommendations!
Published in 2020 at "Advances in Therapy"

DOI: 10.1007/s12325-020-01365-3

Abstract: Resistance to first- and second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) and development and progression of central nervous system metastases remain significant issues in the treatment of ALK-positive non-small-cell lung cancer. Lorlatinib is… read more here.

Keywords: recommendations management; consensus recommendations; management counseling; adverse events ... See more keywords
Photo from wikipedia

Lorlatinib for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer: Results of the IFCT-1803 LORLATU cohort.

Sign Up to like & get
recommendations!
Published in 2022 at "European journal of cancer"

DOI: 10.1016/j.ejca.2022.01.018

Abstract: BACKGROUND Anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) represents a rare subset of lung cancer, with specific presentation, and multiple treatment options, including selective tyrosine kinase inhibitors (TKIs). Real-world evidence is insufficient… read more here.

Keywords: cancer; kinase; lorlatinib; lung cancer ... See more keywords
Photo from wikipedia

Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer

Sign Up to like & get
recommendations!
Published in 2023 at "Cancer Science"

DOI: 10.1111/cas.15777

Abstract: Alectinib, an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), is the recommended first‐line treatment for ALK‐positive non‐small‐cell lung cancer (NSCLC) in Japan. Lorlatinib was approved as a subsequent therapeutic option after progression while receiving… read more here.

Keywords: lung cancer; japanese patients; lorlatinib; line ... See more keywords

A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy

Sign Up to like & get
recommendations!
Published in 2021 at "Journal of Oncology Pharmacy Practice"

DOI: 10.1177/10781552211004698

Abstract: Introduction We report the case of a woman who developed hyperlipidemia on lorlatinib therapy found to have minimal change disease. We review therapies for cancer known to alter the lipid profile, in addition to reviewing… read more here.

Keywords: cancer; lorlatinib therapy; hyperlipidemia; lorlatinib ... See more keywords
Photo from wikipedia

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study

Sign Up to like & get
recommendations!
Published in 2022 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.21.02278

Abstract: PURPOSE Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non–small-cell lung cancer (NSCLC) in the phase III CROWN trial. Here, we report post… read more here.

Keywords: lung cancer; non small; small cell; lorlatinib ... See more keywords